The local medical sector is excited with the introduction of retatrutide, a innovative dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for addressing obesity. This https://infopagex.com/story7223500/retatrutide-australia-a-new-hope-for-weight-loss